SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement

被引:0
作者
Małgorzata Szostakowska
Michał Szymczyk
Kalina Badowska
Barbara Tudek
Anna Fabisiewicz
机构
[1] University of Warsaw,Faculty of Biology
[2] Maria Skłodowska-Curie Institute - Oncology Center,Department of Molecular and Translational Oncology
[3] Maria Skłodowska-Curie Institute - Oncology Center,Department of Lymphoproliferative Diseases
[4] Polish Academy of Sciences,Institute of Biochemistry and Biophysics
来源
Medical Oncology | 2018年 / 35卷
关键词
Minimal residual disease; Mantle cell lymphoma; SOX11; Molecular marker;
D O I
暂无
中图分类号
学科分类号
摘要
The main cause of death in mantle cell lymphoma (MCL) patients is relapse due to undetermined minimal residual disease (MRD) and therefore monitoring MRD is crucial for making the best treatment decisions. The gold standard method for MRD analysis is the quantitative polymerase chain reaction. The most commonly used molecular markers for measuring MRD in MCL are: t(11;14)(q13;p32) translocation or CCND1 expression and IGH rearrangement. Such markers can, however, be found in other B cell non-Hodgkin lymphomas. Recent studies demonstrate that SOX11 expression is highly specific for MCL and could be used as a marker for measuring MRD. Moreover, evidence shows that SOX11 level could be predictive for overall survival (OS) and progression-free survival (PFS). We have measured MRD level in follow-up samples from 27 patients diagnosed with MCL using the molecular markers: t(11;14), IGH rearrangement and SOX11 expression. We compared all markers by their sensitivity, utility and quantitative range. We also examined the predictive value of SOX11 expression for OS and PFS. SOX11 expression was found to have better specificity, quantitative range and utility than the t(11;14). The predictive value of SOX11 expression was confirmed. At diagnosis, patients with high SOX11 expression had shorter PFS than patients with low SOX11 expression (p = 0.04*); differences between OS being statistically insignificant. To our best knowledge this is a first study comparing SOX11 with t(11;14) and IGH rearrangement as markers of MRD level. Moreover, in this study we confirmed that SOX11 is useful in cases when other molecular markers cannot be used.
引用
收藏
相关论文
共 31 条
[21]   Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma [J].
Dictor, Michael ;
Ek, Sara ;
Sundberg, Maria ;
Warenholt, Janina ;
Gyorgy, Czabafy ;
Sernbo, Sandra ;
Gustavsson, Elin ;
Abu-Alsoud, Waleed ;
Wadstrom, Torkel ;
Borrebaeck, Carl .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11) :1563-1568
[22]   Molecular methods for detecting t(11;14) translocations in mantle-cell lymphomas [J].
Fan, HX ;
Gulley, ML ;
Gascoyne, RD ;
Horsman, DE ;
Adomat, SA ;
Cho, CG .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1998, 7 (04) :209-214
[23]   Primary large B-cell lymphoma of the central nervous system with cyclinD1expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma withCCND1rearrangement or mantle cell lymphoma? [J].
Parrott, Andrew M. ;
Haggiagi, Aya M. ;
Murty, Vundavalli V. ;
Bhagat, Govind ;
Alobeid, Bachir .
HEMATOLOGICAL ONCOLOGY, 2020, 38 (05) :817-822
[24]   Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia [J].
Tarsitano, Marina ;
Palmieri, Salvatore ;
Ferrara, Felicetto ;
Riccardi, Cira ;
Cavaliere, Maria Luigia ;
Vicari, Laura .
CANCER GENETICS AND CYTOGENETICS, 2009, 195 (02) :164-167
[25]   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Cyclin D1 Positive Proliferation Centers Do Not Have CCND1 Translocations or Gains and Lack SOX11 Expression [J].
Gradowski, Joel F. ;
Sargent, Rachel L. ;
Craig, Fiona E. ;
Cieply, Kathleen ;
Fuhrer, Kim ;
Sherer, Carol ;
Swerdlow, Steven H. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (01) :132-139
[26]   Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review [J].
Manda-Mapalo, M. T. ;
Khalili, P. ;
Quintana, D. ;
Rabinowitz, I. ;
Zhang, Q. Y. .
CANCER GENETICS, 2016, 209 (10) :481-485
[27]   The t(11;14)(q13;q32)/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia [J].
Schliemann, Igor ;
Oschlies, Ilske ;
Nagel, Inga ;
Penas, Eva Maria Murga ;
Siebert, Reiner ;
Sander, Birgitta .
LEUKEMIA & LYMPHOMA, 2016, 57 (11) :2672-2676
[28]   A t(11;14)(q13;q32)/CCND1::IGH carrying progenitor germinal B-cell with subsequent cytogenetic aberrations contributes to the development of classic Hodgkin lymphoma [J].
Garcia, Rolando ;
Timmons, Charles ;
Luu, Hung ;
Miller, Valerie ;
Fuda, Franklin ;
Chen, Weina ;
Koduru, Prasad .
CANCER GENETICS, 2022, 268 :97-102
[29]   Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma [J].
Finn, WG ;
Sreekumar, A ;
Menon, A ;
Utiger, C ;
Chinnaiyan, A .
LEUKEMIA & LYMPHOMA, 2006, 47 (01) :121-127
[30]   Quantitative PCR detection of t(11;14) bcl-1/JH in mantle cell lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples [J].
Di Martino, S. ;
Catapano, O. ;
Siesto, S. R. ;
Di Paolo, M. ;
Pugliese, S. ;
Morelli, C. D. ;
Fiorica, F. ;
Varriale, E. ;
Di Francia, R. ;
Abbadessa, A. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (24) :4801-4810